02.01.24 -- When A Rare Disease Partnership Evolves Into A Global Effort

Employee turnover, even during complex clinical trials, should never be the breaking point of a project. Avoid these instances and keep studies on track by developing proactive employee retention strategies.

While the U.S. market remains the primary focus for most EBPs, they need to broaden their horizons to maximize product value. Dive into this compelling case for launching in Europe and how to succeed.

Discover how clients were able to leverage the extensive resources of PPD FSP Pharmacovigilance globally, maximizing their PV operational delivery model and successfully meeting ambitious timelines.

While a few red flags are common during any regulatory submission, several occurring in concert can precipitate a crisis. Learn who you can turn to for help and when it's time to seek assistance.

In December 2023, the FDA released the final version of its digital health technologies guidance, outlining the facilitated use of sensor-based DHTs and wearables in clinical investigations.

The National Institutes of Health (NIH) estimates that one in 10 Americans are affected by a rare disease or condition. Explore global challenges and regulatory frameworks for rare diseases in this presentation.

Get support from clinical regulatory specialists with expertise in creating clinical and drug development plans, GMP compliance, designing and coordinating GLP-compliant toxicology studies, and more.